New pill for rare lung and liver disease passes first safety check

NCT ID NCT06738017

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 25 times

Summary

This early-stage trial tests a single oral dose of BMN 349 in 6 adults with a genetic form of alpha-1 antitrypsin deficiency (PiZZ or PiMZ/MASH). The main goal is to see if the drug is safe and how the body processes it. Participants receive either BMN 349 or a placebo and are closely monitored for side effects and changes in lab tests, lung function, and heart activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Medpace Clinical Pharmacology Unit

    Cincinnati, Ohio, 45227, United States

  • NHS Lothian

    Edinburgh, UK, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, UK, United Kingdom

  • Saint Louis University

    St Louis, Missouri, 63110, United States

  • The Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • University Hospital Southampton NHS Foundation Trust

    Southampton, UK, United Kingdom

  • University of California, San Diego

    San Diego, California, 92037, United States

Conditions

Explore the condition pages connected to this study.